Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed).
Adolescent
Body Composition
Body Mass Index
Bone Neoplasms
/ physiopathology
Child
Female
Humans
Infections
/ epidemiology
Male
Malnutrition
/ complications
Nutrition Assessment
Nutritional Status
Pilot Projects
Prognosis
Retrospective Studies
Rhabdomyosarcoma
/ physiopathology
Sarcoma
/ physiopathology
Sarcoma, Ewing
/ physiopathology
Sarcopenia
/ epidemiology
Survival Rate
bone sarcoma
chemotherapy
pediatric patients
personalized medicine
psoas muscle area (PMA)
sarcopenia
soft tissue sarcoma
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
17 Jan 2022
17 Jan 2022
Historique:
received:
22
12
2021
revised:
13
01
2022
accepted:
14
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
28
1
2022
Statut:
epublish
Résumé
We evaluated nutritional and sarcopenia status and their clinical impact in pediatric patients affected by bone and soft tissue sarcomas. Body mass index (BMI), prognostic nutritional index (PNI), and total psoas muscle area (tPMA) at diagnosis and after 12 months were analyzed. tPMA was measured from single cross-sectional computed tomography (CT) images at L4-L5. Age-specific and sex-specific tPMA Z-scores were retrieved from an online calculator. A total of 21 patients were identified between February 2013 and December 2018. Twelve patients (57.1%) experienced sarcopenia at diagnosis, although not statistically associated with overall survival (OS) ( Sarcopenia affects more than half of the patients at diagnosis. Decreased PNI during 12 months of treatment has significant predictive value for OS. The role of tPMA derived from CT scan among pediatric patients with sarcoma should be investigated in further prospective and larger studies.
Sections du résumé
BACKGROUND
BACKGROUND
We evaluated nutritional and sarcopenia status and their clinical impact in pediatric patients affected by bone and soft tissue sarcomas.
METHODS
METHODS
Body mass index (BMI), prognostic nutritional index (PNI), and total psoas muscle area (tPMA) at diagnosis and after 12 months were analyzed. tPMA was measured from single cross-sectional computed tomography (CT) images at L4-L5. Age-specific and sex-specific tPMA Z-scores were retrieved from an online calculator.
RESULTS
RESULTS
A total of 21 patients were identified between February 2013 and December 2018. Twelve patients (57.1%) experienced sarcopenia at diagnosis, although not statistically associated with overall survival (OS) (
CONCLUSIONS
CONCLUSIONS
Sarcopenia affects more than half of the patients at diagnosis. Decreased PNI during 12 months of treatment has significant predictive value for OS. The role of tPMA derived from CT scan among pediatric patients with sarcoma should be investigated in further prospective and larger studies.
Identifiants
pubmed: 35057564
pii: nu14020383
doi: 10.3390/nu14020383
pmc: PMC8781939
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):8-11
pubmed: 15990621
Curr Opin Clin Nutr Metab Care. 2012 May;15(3):303-9
pubmed: 22588189
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):405-414
pubmed: 31920002
Acute Med Surg. 2016 May 02;3(4):326-331
pubmed: 29123807
Urol Oncol. 2015 Feb;33(2):68.e1-7
pubmed: 25240758
J Pediatr (Rio J). 2016 Jul-Aug;92(4):343-52
pubmed: 26859247
Curr Protein Pept Sci. 2018 May 14;19(7):633-638
pubmed: 28595526
J Cell Physiol. 2019 Feb;234(2):1794-1802
pubmed: 30070689
Pediatr Blood Cancer. 2013 Apr;60(4):642-9
pubmed: 23281136
Mol Aspects Med. 2005 Jun;26(3):181-201
pubmed: 15811434
Eur J Gastroenterol Hepatol. 2015 Mar;27(3):328-34
pubmed: 25569567
Korean J Pediatr. 2015 Oct;58(10):363-8
pubmed: 26576179
Front Physiol. 2012 Jul 11;3:260
pubmed: 22934016
Pediatr Blood Cancer. 2021 May;68(5):e28862
pubmed: 33438330
Eur J Surg Oncol. 2021 Oct 16;:
pubmed: 34696936
Curr Opin Pediatr. 2008 Oct;20(5):590-6
pubmed: 18781124
J Crit Care. 2018 Jun;45:7-13
pubmed: 29360610
J Cancer Res Clin Oncol. 2015 Feb;141(2):307-13
pubmed: 25124497
Blood Adv. 2021 Nov 23;5(22):4619-4629
pubmed: 34610115
Am J Clin Nutr. 2010 Jul;92(1):55-60
pubmed: 20484453
Clin Interv Aging. 2017 Oct 04;12:1615-1625
pubmed: 29042762
Calcif Tissue Int. 2013 Sep;93(3):201-10
pubmed: 23842964
Support Care Cancer. 2015 Jan;23(1):143-50
pubmed: 25011521
JPEN J Parenter Enteral Nutr. 2013 Jul;37(4):460-81
pubmed: 23528324
J Cancer Res Clin Oncol. 2017 Jul;143(7):1263-1273
pubmed: 28247035
Curr Opin Pulm Med. 2006 Nov;12(6):422-7
pubmed: 17053492
Hormones (Athens). 2018 Sep;17(3):321-331
pubmed: 30014320
Nutr Rev. 2015 May;73(5):276-95
pubmed: 26011902
Tech Innov Patient Support Radiat Oncol. 2020 Nov 09;16:50-57
pubmed: 33385074
Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2690-2701
pubmed: 28678315
Syst Rev. 2018 Mar 27;7(1):51
pubmed: 29587829
J Natl Cancer Inst Monogr. 2019 Sep 1;2019(54):144-148
pubmed: 31532526
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Eur J Clin Nutr. 2021 Oct 7;:
pubmed: 34621000
JPEN J Parenter Enteral Nutr. 2020 Mar;44(3):407-418
pubmed: 31328301
Nutr Clin Pract. 2015 Oct;30(5):609-24
pubmed: 26330113
J Ren Nutr. 2016 Jul;26(4):258-64
pubmed: 26994780
Eur Rev Med Pharmacol Sci. 2019 Jan;23(3):1165-1175
pubmed: 30779086
Am J Transplant. 2016 Aug;16(8):2277-92
pubmed: 26813115
Crit Care. 2013 Sep 19;17(5):R206
pubmed: 24050662
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
J Pediatr Hematol Oncol. 2013 Mar;35(2):98-102
pubmed: 23242330
Clin Nutr. 2019 Oct;38(5):2002-2015
pubmed: 31031136
Orthop Surg. 2016 May;8(2):122-8
pubmed: 27384720
J Gerontol A Biol Sci Med Sci. 2019 Sep 15;74(10):1671-1678
pubmed: 30726878
J Surg Res. 2019 Apr;236:101-105
pubmed: 30694741
BMC Geriatr. 2020 Nov 25;20(1):500
pubmed: 33238889
Asian Pac J Cancer Prev. 2015;16(18):8075-7
pubmed: 26745041